The effect of betahistine on prevention of olanzapine-induced weight gain in patients with psychotic disorder
Phase 2
- Conditions
- Psychosis.Unspecified psychosis not due to a substance or known physiological condition
- Registration Number
- IRCT20210409050910N2
- Lead Sponsor
- Sabzevar University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not all people with psychosis are treated with olanzapine and do not take effective histamine receptors (antihistamines, etc.).
Exclusion Criteria
Patients with concomitant metabolic diseases
Patients who are obese.
Patients taking other weight gain drugs (such as clozapine) at the same time.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weight: The rate of weight gain in control and intervention groups. Timepoint: Start treatment, weeks 4 and 8 and end treatment. Method of measurement: Scales.;Waist circumference: The rate of increase in waist circumference in control and intervention groups. Timepoint: Start treatment, weeks 4 and 8 and end treatment. Method of measurement: Meter.
- Secondary Outcome Measures
Name Time Method